Medical management of mild-to-moderate heart failure before the advent of beta blockers

American Journal of Medicine

Volumn 110, Issue 7, 2001, Pages 47-62

  Abraham, William T ^a,c   Wagoner, Lynne E ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMILORIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; METOLAZONE; MILRINONE; NITRATE; PRAZOSIN; SPIRONOLACTONE; TORASEMIDE; TRIAMTERENE; UNINDEXED DRUG; VASODILATOR AGENT;

ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; BETA ADRENERGIC RECEPTOR BLOCKING; CALCIUM ANTAGONISM; CLINICAL TRIAL; DIURETIC THERAPY; DRUG EFFECT; DRUG EFFICACY; HEART FAILURE; HUMAN; HYPOKALEMIA; HYPONATREMIA; ISCHEMIA; PRIORITY JOURNAL; REVIEW;

EID: 20444385919     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00386-6     Document Type: Review

References (105)

1. Effect of oral milrinone on mortality in severe chronic heart failure
2. Xamoterol in severe heart failure
3. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo
4. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
5. Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
6. The treatment of heart failure: Guidelines
7. Consensus recommendations for the management of heart failure
8. Heart Failure Society of America guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
9. Results of coronary artery surgery in patients with poor left ventricular function (CASS)
10. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction
11. Surgical survival benefits for coronary disease patients with left-ventricular dysfunction
12. Reversal of chronic ischemic myocardial dysfunction after transluminal coronary angioplasty
13. Coronary artery bypass grafting in severe left ventricular dysfunction: Excellent survival with improved ejection fraction and functional state
14. Ischemic cardiomyopathy: Medical versus surgical treatment
15. Resolution of congestive failure, mitral regurgitation, and angina after percutaneous transluminal coronary angioplasty of triple vessel disease
16. Coronary artery bypass grafts for congestive heart failure: A report of experiences with 40 patients
17. A clinical trial of immunosuppressive therapy for myocarditis
18. Intervention in myocarditis and acute cardiomyopathy with immune globulin: Results from the randomized placebo controlled IMAC trial
19. The natural course of alcoholic cardiomyopathy
20. Importance of abstention from alcohol in alcoholic heart disease
21. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure
22. Acute oliguric renal failure induced by indomethacin: Possible mechanism
23. Effects of physical training in chronic heart failure
24. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function
25. Cardiac rehabilitation for heart failure patients
26. Arm exercise training in the rehabilitation of patients with impaired ventricular function and heart failure
27. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance
28. Exercise training in patients with severe left-ventricular dysfunction: Hemodynamic and metabolic effects
29. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
30. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
31. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
32. A study by continuous microperfusion of water and electrolyte movements in the loop of Henle and distal tubule of the rat
33. Renal potassium excretion
34. 2 receptor vasopressin antagonist in patients with chronic heart failure
35. Effect of diuresis on the performance of the failing left ventricle in man
36. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics
37. Aldosterone in congestive heart failure patients: Analysis of determinants and role in sodium retention
38. The physiologic basis of diuretic synergism: Its role in treating diuretic resistance
39. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention
40. Crossover comparison of the fixed combination of furosemide and triamterene and the free combination of furosemide and triamterene in the maintenance treatment of congestive heart failure
41. Enalapril in patients with chronic heart failure: A placebo-controlled, randomized, double-blind study
42. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure
43. Enalapril for severe congestive heart failure: A double-blind study
44. Comparison of lisinopril versus placebo for congestive heart failure
45. Captopril in mild heart failure: Preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial
46. Controlled trial of enalapril in congestive cardiac failure
47. Enalapril in chronic heart failure, a double-blind placebo-controlled study
48. A placebo-controlled trial of captopril in refractory chronic congestive heart failure
49. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
50. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure
51. Placebo-controlled study of lisinopril in congestive heart failure: A multicentre study
52. Hemodynamic effects of captopril in patients with severe heart failure
53. Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations
54. Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of chronic congestive heart failure
55. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction
56. Effects of enalapril on mortality in severe congestive heart failure
57. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure
58. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction
59. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
60. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
61. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
62. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
63. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: The healing and early afterload reducing therapy trial
64. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
65. The effect of digoxin on mortality and morbidity in patients with heart failure
66. Acute effects of digoxin on total SVR in congestive heart failure due to dilated cardiomyopathy: A hemodynamic-hormonal study
67. Sympathoinhibitory responses to digitalis glycosides in heart failure patients
68. Long-term digitalis therapy improves left ventricular function in heart failure
69. Heart failure in outpatients: A randomized trial of digoxin versus placebo
70. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial
71. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors
72. Superiority of "triple" drug therapy in heart failure: Insights from the PROVED and RADIANCE trials
73. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation
74. Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure
75. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
76. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study
77. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure
78. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure
79. Afterload reduction: A comparison of captopril and nifedipine in dilated cardiomyopathy
80. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction
81. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III
82. Effect of amlodipine on morbidity and mortality in severe heart failure
83. Preliminary results of the Second Prospective Amlodipine Survival Evaluation
84. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
85. Losartan in heart failure: Hemodynamic effects and tolerability
86. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure
87. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition
88. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study
89. Development of arrhythmias in the patient with congestive heart failure: Pathophysiology, prevalence, and prognosis
90. Ventricular arrhythmias in severe heart failure: Incidence, significance, and effectiveness of antiarrhythmic therapy
91. Sudden death in idiopathic dilated cardiomyopathy
92. Electrophysiology, pacing, and arrhythmia: Ventricular arrhythmias in congestive heart failure
93. Sudden death in patients with congestive heart failure: Future directions
94. Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias
95. Aggravation of arrhythmia by antiarrhythmic drugs - Incidence and predictors
96. Clinical haemodynamic and antiarrhythmic effects of long term treatment with amiodarone of patients with heart failure
97. Ventricular arrhythmias in dilated cardiomyopathy: Efficacy of amiodarone
98. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy
99. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)
100. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure
101. Management of heart failure. IV anticoagulation for patients with heart failure due to left ventricular systolic dysfunction
102. Intracardiac thrombi and systemic embolization
103. Incidence of thromboembolic events in congestive heart failure
104. Antithrombotic therapy in heart failure: Controversies and recent developments